200 Sidney Street
About Translate BioTranslate Bio is a leading biotechnology company focused on pioneering the translation of RNA science into therapeutics promoting healthy gene expression in people living with debilitating genetic diseases. The company’s RNA platforms for powering endogenous therapeutic protein production is applicable to a broad range of diseases including rare diseases of the liver, lung and central nervous system (CNS).
CEO: Ronald C. Jr.
CSO: Thomas McCauley
CTO: Michael Heartlein
CBO: Brian Fenton
Please click here for Translate Bio job opportunities.
FOLLOW TRANSLATE BIO:
Tweets by Translate Bio
16 articles with Translate Bio
The annual meeting of the American Society of Gene & Cell Therapy (ASGCT) was held in Washington, DC this week, with literally hundreds of abstracts and presentations. Here’s a look at some of the highlights.
Messenger RNA (mRNA) is a family of RNA molecules that transport genetic information from DNA to the ribosome, where it specifies the amino acid sequence that creates proteins. In theory, by coding your own mRNA, it should be possible to insert it into the cells and turn them into protein factori...
Translate Bio did not provide information as to what questions or concerns the FDA has regarding the planned early-stage trial for mRT5201.
1/4/2019Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more.
Most of the IPOs that occurred in the Bay State have been well-documented by BioSpace. But, with a new calendar year upon us, it’s a good idea to look back at a banner year of capitalization that may not repeat when January rolls around. With the turn of the year only days away, BioSpace takes a ...
According to BioPharmCatalyst, there have been (or soon will be) 58 biopharma initial public offerings (IPOs) in 2018, and there’s still more than three months to go.
It’s been a pretty good year for mergers and acquisitions in the biopharma industry. But the landscape for IPOs has been excellent as well, particularly in Massachusetts, which has recorded 13 IPOs since the beginning of the year.
Translate Bio today announced that it has launched an initial public offering of 7,700,000 shares of its common stock.
Translate Bio, headquartered in Lexington, Massachusetts, and Paris-based Sanofi are teaming up to develop five vaccines.
Translate Bio Announces Agreement with Sanofi Pasteur to Develop Vaccines for Infectious Diseases using Novel mRNA Technology
Translate Bio announced today a multi-year research and development collaboration and exclusive licensing agreement with Sanofi Pasteur.
41st Annual European Cystic Fibrosis Conference is taking place in Belgrade, Serbia, from June 7-10, 2018.
Eight biotechs launched initial public offerings (IPO) in May, April wasn’t as hot a month, with only two. But June is off to a good start with two.
Mr. Schroer brings expertise in financial strategy and analysis and strong industry relationships to Translate Bio.
Translate Bio Announces FDA Clearance to Proceed with Phase 1/2 Clinical Trial in Patients with Cystic Fibrosis (CF)
mRNA therapeutic product candidate MRT5005 designed to treat all patients with CF regardless of underlying genetic mutation
Translate Bio today announced the appointment of Ann Barbier, M.D., Ph.D., as chief medical officer, effective immediately.